ABITEC Acquires Larodan for Lipid Product Expansion

Article

Through the acquisition, the companies plan to build a global science-based organization that uses product innovation to enhance ABITEC’s scientific and commercial interests.

ABITEC, an ABF Ingredients company, announced on July 8, 2020 that it has acquired Larodan AB, a Sweden-based manufacturer and international marketer of high-purity research grade lipids, to expand its lipid product offerings and scientific capabilities.

Through the acquisition, the companies plan to build a global science-based organization that uses product innovation to enhance ABITEC’s scientific and commercial interests, an ABITEC press release said. Additionally, the acquisition will introduce ABITEC to the field of Lipidomics which gives researchers the ability to identify the roles of lipids across various health and disease states at the chemical level.

“Larodan is a world leader in the field of analytical-grade lipids, and their scientific capabilities will not only expand ABITEC’s technical expertise but will also provide us with a strategic R&D location in Europe. The Larodan team has done an exceptional job in the development, manufacturing, and global commercialization of their unique and highly specialized lipid reagents, and we are thrilled to have them join the ABITEC team. We share a common passion for innovation and lipids, and I look forward to us working together to grow and expand their brand in the US markets and across the globe,” said Jeff Walton, CEO of ABITEC, in the press release.

“We are very happy to find a new home with ABITEC, with whom we share a deep interest in lipids. Together we can immediately offer a more comprehensive service to our American customers, including larger volumes and GMP grades,” said Fredrik Lindgren, selling shareholder and continuing managing director of Larodan, in the press release.

Source: ABITEC

 

Recent Videos
Behind the Headlines, episode 7
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content